Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...
Long Island acupuncture clinic expands services with AcuNova Acupuncture, a specialized approach designed to support ...
If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...
Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback